From its formation in 2001, Pieris has come a long way. Since 2009, it has entered into a number of licensing deals after other companies approached Pieris expressing a need for a new therapeutic.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
4 May 2017 AstraZeneca has entered into a collaboration with biotech company Pieris Pharmaceuticals to develop novel inhaled drugs that expand on Pieris’s Anticalin platform.
4 May 2017 AstraZeneca has entered into a collaboration with biotech company Pieris Pharmaceuticals to develop novel inhaled drugs that expand on Pieris’s Anticalin platform.
4 May 2017 AstraZeneca has entered into a collaboration with biotech company Pieris Pharmaceuticals to develop novel inhaled drugs that expand on Pieris’s Anticalin platform.